Four Part Interview - Ron Nahass, MD discusses HCV and The Future of Infectious Disease Treatment

Part 1 -4 is provided below, Specialty Pharmacy Times published part 4 of the interview today.

The Future of Infectious Disease Treatment
In part four of a 4-part exclusive interview with Specialty Pharmacy Times, Ron Nahass, MD, MHCM, FACP, FIDSA, discusses the impact of antiretrovirals and new blockbuster HCV drugs, challenges in the field, patient adherence, telehealth, and more.

Dr Nahass has been conducting infectious disease medicine for almost 30 years. He has had a long career in clinical research, and education in the area of chronic viral diseases, including HCV, hepatitis B, and HIV. He currently serves on the American Association for the Study of Liver Disease (AASLD) panel HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.

Part 1

The Changing Landscape of HIV Treatment

2017.04.12

Lauren Santye, Assistant Editor

Part 1 of a 4-part interview with an infectious disease expert explores treatment advances in HIV since the AIDS epidemic in the 1980s.

Part 2

The Challenges in Treating Patients with High Cost Hepatitis C Drugs

2017.04.13

Lauren Santye, Assistant Editor

The second of 4-part interview with an infectious disease expert examines weighing the short-term high cost of treating HCV with curative drugs versus the long-term costs of treating the disease.

Part 3

Specialty Drugs Change Infectious Disease Treatment

2017.04.17

Lauren Santye, Assistant Editor

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.

Part 4

The Future of Infectious Disease Treatment

2017.04.18

Lauren Santye, Assistant Editor

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.